Latest Legal Fees News

DGR Global Limited reported steady progress in project generation and strategic investments during Q1 2025, while navigating ongoing legal challenges and securing a $23.5 million funding facility to support operations and refinancing.

Health and Plant Protein Group Limited has dramatically reduced its half-year net loss to $43,000 following the divestment of its macadamia division, though uncertainty lingers over a significant IRS receivable in the US.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.

Nagambie Resources has updated its JORC Inferred Resource at the Nagambie Mine, reflecting higher gold and antimony prices and ongoing drilling efforts to expand and upgrade the deposit.

Conico Ltd is exploring strategic options to enhance its Mt Thirsty cobalt-nickel project while navigating a significant arbitration ruling over drilling contracts in Greenland. The company also signals ongoing evaluation of new mineral exploration opportunities.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

SIV Capital Limited reported a negative operating cash flow for Q2 FY25 and remains suspended from ASX trading due to compliance issues, while actively exploring acquisition opportunities.

Energy World Corporation Ltd. reports significant board changes and strategic committee formations as it navigates a quarter marked by operational cash outflows but maintains a solid cash reserve.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

Raptis Group Limited reported stable income from its caretaking and letting operations for the December 2024 quarter, while navigating a personal injury claim and exploring a new residential resort project on the Gold Coast.